Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 845-854

  Wysocki, Christian A ^a   Burkett, Susan B ^a   Panoskaltsis Mortari, Angela ^b   Kirby, Suzanne L ^a   Luster, Andrew D ^c   McKinnon, Karen ^a   Blazar, Bruce R ^b   Serody, Jonathan S ^a,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE CCL4; CHEMOKINE RECEPTOR CCR5; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CELL SURVIVAL; COLON; CONDITIONING; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOPATHOLOGY; LIVER; LUNG; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN;

EID: 3142661927     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.845     Document Type: Article

References (56)

1. Blazar, B. R., R. Korngold, and D. A. Vallera. 1997. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol. Rev. 157:79.
2. Baker, M. B., N. H. Altman, E. R. Podack, and R. B. Levy. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645.
3. Kataoka, Y., T. Iwasaki, T. Kuroiwa, Y. Seto, N. Iwata, N. Hashimoto, A. Ogata, T. Hamano, and E. Kakishita. 2001. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 103:310.
4. Prentice, H. G., H. A. Blacklock, G. Janossy, K. F. Bradstock, D. Skeggs, G. G., and H. A. V. 1982. Use of anti-T cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet 1:700.
5. + T cells. J. Immunol. 155:2396.
6. Krenger, W., G. R. Hill, and J. L. Ferrara. 1997. Cytokine cascades in acute graft-versus-host disease. Transplantation 64:553.
7. Herve, P., M. Flesch, P. Tiberghien, J. Wijdenes, E. Racadot, P. Bordigoni, P. Plouvier, J. L. Stephan, H. Bourdeau, E. Holler, et al. 1992. Phase I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79:3362.
8. Hill, G. R., J. M. Crawford, K. R. Cooke, Y. S. Brinson, L. Pan, and J. L. Ferrara. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204.
9. Speiser, D. E., M. F. Bachmann, T. W. Frick, K. McKall-Faienza, E. Griffiths, K. Pfeffer, T. W. Mak, and P. S. Ohashi. 1997. TNF receptor p55 controls early acute graft-versus-host disease. J. Immunol. 158:5185.
10. Hill, G. R., T. Teshima, A. Gerbitz, L. Pan, K. R. Cooke, Y. S. Brinson, J. M. Crawford, and J. L. Ferrara. 1999. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft-versus-leukemia. J. Clin. Invest. 104:459.
11. 1 mice. J. Immunol. 168:3065,
12. Ferrara, J. L., K. R. Cooke, L. Pan, and W. Krenger. 1996. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 14:473.
13. 1 hybrid model is dependent on the Fas pathway. Immunology 99:94.
14. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657.
15. Graubert, T. A., J. F. DiPersio, J. H. Russell, and T. J. Ley. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100:904.
16. Baker, M. B., R. L. Riley, E. R. Podack, and R. B. Levy. 1997. Graft-versus-host disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc. Natl. Acad. Sci. USA 94:1366.
17. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64:571.
18. Hattori, K., T. Hirano, H. Miyajima, N. Yamakawa, M. Tateno, K. Oshimi, N. Kayagaki, H. Yagita, and K. Okumura. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor a antibodies on acute graft-versus-host disease pathologies. Blood 91:4051.
19. Schmaltz, C., O. Alpdogan, K. J. Homdasch, S. J. Muriglan, B. J. Kappel, T. Teshima, J. L. Ferrara, S. J. Burakoff, and M. R. M. van den Brink. 2001. Differential use of fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97:2886.
20. Rao, A. R., M. P. Quinones, E. Garavito, Y. Kalkonde, F. Jimenez, C. Gibbons, J. Perez, P. Melby, W. Kuziel, R. L. Reddick, et al. 2003. CC Chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease. J. Immunol. 171:4875.
21. + T cells to the liver, lung and spleen during graft-versus-host disease. Blood 96:2973.
22. Serody, J. S., D. N. Cook, S. L. Kirby, E. Reap, T. C. Shea, and J. A. Frelinger. 1999. Murine T lymphocytes incapable of producing MIP-1α are impaired in causing GVHD across a class I but not class II MHC barrier. Blood 93:43.
23. Duffner, U., B. Lu, G. C. Hildebrandt, T. Teshima, D. L. Williams, P. Reddy, R. Ordemann, S. G. Clouthier, K. Lowler, C. Liu, et al. 2003. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp. Hematol. 31:897.
24. Panoskaltsis-Mortari, A., J. R. Hermanson, E. Taras, O. D. Wangensteen, J. S. Serody, and B. R. Blazar. 2003. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1α (CCL3) post allogeneic BMT in mice. Blood 101:3714.
25. + T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104:49.
26. Murai, M., H. Yoneyama, T. Ezaki, M. Suematsu, Y. Terashima, A. Harada, H. Hamada, H. Asakura, H. Ishikawa, and K. Matsushima. 2003. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat. Immunol. 4:154.
27. Mellado, M., J. M. Rodriguez-Frade, S. Manes, and Martinez A. C., 2001. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol. 19:397.
28. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121.
29. Ngo, V. N., H. L. Tang, and J. Cyster, G. 1998. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J. Exp. Med. 188:181.
30. Campbell, J. J., E. P. Bowman, K. Murphy, K. R. Youngman, M. A. Siani, D. A. Thompson, L. Wu, A. Zlotnik, and E. C. Butcher. 1998. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7. J. Cell Biol. 141:1053.
31. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 Coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23.
32. Bonecchi, R., G. Bianchi, P. P. Bordignon, D. D'Ambrosio, R. Lang, A. Borsatti, S. Sozzani, P. Allavena, P. A. Gray, A. Mantovani, et al. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:129.
33. Loetscher, P., M. Uguccioni, L. Bordoli, M. Baggiolini, B. Moser, C. Chizzolini, and J.-M. Dayer. 1998. CCR5 is characteristic of Th1 lymphocytes. Nature 391:344.
34. Luttrell, L. M., and R. J. Lefkowitz. 2002. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115:455.
35. Szabo, I., X.-H. Chen, L. Xin, M. Adler, O. M. Z. Howard, J. J. Oppenheim, and T. J. Rogers. 2002. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. USA 99:10276.
36. Hecht, I., L. Cahalon, R. Hershkoviz, A. Lahat, S. Franitza, and O. Lider. 2003. Heterologous desensitization of T cell functions by CCR5 and CXCR4 ligands: inhibition of cellular signaling, adhesion and chemotaxis. Int. Immunol. 15:29.
37. Honczarenko, M., Y. Le, A. M. Glodek, M. Majka, J. J. Campbell, M. Z. Ratajczak, and L. E. Silberstein. 2002. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 100:2321.
38. Blackwood, R. A., K. T. Hartiala, E. E. Kwoh, A. T. Transue, and R. C. Brower. 1996. Unidirectional heterologous desensitization between both the fMLP and C5a receptor and the IL-8 receptor. J. Leukocyte Biol. 60:88.
39. New, J. Y., B. Li, W. P. Koh, H. K. Ng, S. Y. Tan, E. H. Yap, S. H. Chan, and H. Z. Hu. 2002. T-cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 29:979.
40. Tamotsu, I., T. Teshima, R. Kuick, D. E. Misek, C. Liu, Y. Takada, Y. Maeda, P. Reddy, D. L. Williams, S. M. Hanash, et al. 2003. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood 102:763.
41. Zhang, Y., L. L. McCormick, S. R. Desai, C. Wu, and A. C. Gilliam. 2002. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J. Immunol. 168:3088.
42. Kuziel, W. A., T. C. Dawson, M. Quinones, E. Garavito, G. Chenaux, S. S. Ahuja, R. L. Reddick, and N. Maeda. 2003. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167:25.
43. Khan, I. A., J. A. MacLean, F. S. Lee, L. Casciotti, E. DeHaan, J. D. Schwartzman, and A. D. Luster. 2000. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12:483.
44. van den Brink, M. R. M., E. Moore, K. J. Homdasch, J. M. Crawford, J. Hoffman, G. F. Murphy, and S. J. Burakoff. 2000. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J. Immunol. 164:469.
45. Blazar, B. R., P. A. Taylor, R. McElmurry, L. Tian, A. Panoskaltsis-Mortari, S. Lam, C. Lees, T. Wasdschmidt, and D. A. Vallera. 1998. Engraftment of severe combined immune deficient (SCID) mice receiving allogeneic bone marrow (BM) via in utero or post-natal transfer. Blood 92:3949.
46. Nakajima, C., M. T., N. Yamaguchi, Y. Morimoto, W. Park, M. Iwasaki, P. Gao, S. Ono, H. Fujiwara, and T. Hamaoka. 2002. Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-γ stimulation. Eur. J. Immunol. 32:1792.
47. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457.
48. Sato, N., W. A. Kuziel, P. C. Melby, R. L. Reddick, V. Kostecki, W. Zhao, N. Maeda, S. K. Ahuja, and S. S. Ahuja. 1999. Defects in the generation of IFN-γ are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1α-, or CCR2-deficient mice. J. Immunol. 163:5519.
49. Zhou, Y., T. Kurihara, R. P. Ryseck, Y. Yang, C. Ryan, J. Loy, G. Warr, and R. Bravo. 1998. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:4018.
50. + T cell-mediated acute graft-versus-host disease. J. Clin. Invest. 109:1335.
51. van Leeuwen, L., A. Guiffre, K. Atkinson, S. P. Rainer, and W. A. Sewell. 2002. A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplant. 29:151.
52. 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 103:1542.
53. Mehal, W. Z., F. Azzaroli, and I. N. Crispe. 2001. Antigen presentation by liver cells controls intrahepatic T cell trapping, whereas bone marrow-derived cells preferentially promote intrahepatic T cell apoptosis. J. Immunol. 167:667.
54. Hancock, W. W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J. A. King, S. T. Smiley, M. Ling, N. P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192:1515.
55. Hancock, W. W., W. Gao, V. Csizmadia, K. L. Faia, N. Shemmeri, and A. D. Luster. 2001. Donor-derived IP-10 initiates development of acute allograft rejection. J. Exp. Med. 193:975.
56. Panoskaltsis-Mortari, A., A. Price, J. R. Hermanson, E. Taras, C. Lees, J. S. Serody, and B. R. Blazar. 2004. In vivo imaging of graft-versus-host- disease (GHVD) in mice. Blood 8:8.